HIMS Healthcare

Hims & Hers Health, Inc.

$25.70+1.82%

Price as of close on Nov 3, 2026 · Financials updated Oct 9, 2026

Basics

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Country: United States
Market cap: 6.0B USD
Enterprise value: 6.7B USD
Full-time employees: 2,442

Overall health

Strength: growing faster than most peersgrowing faster than peers
Drawback: less profitable than most peersless profitable than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings
Drawback: higher risk than most peers: its share price swings more than most peers’ (beta 2.43 vs a peer median of 0.63), less short-term liquidity (current ratio 0.93 vs a peer median of 2.59) and more debt relative to equity (4.77× vs a peer median of 0.22×)higher risk: bigger price swings (beta 2.43 vs peers 0.63), less liquidity (current ratio 0.93 vs peers 2.59) and more debt vs equity (4.77× vs peers 0.22×)

Ranks #980 of 1,157 healthcare companies (bottom 16%)

See how it ranks against its peers

Worth knowing

Stock pay outran buybacks. Stock-based pay expense $294M vs $175M spent repurchasing shares over the 3 fiscal years to 2025.
Over three fiscal years Hims & Hers Health recorded $294M of stock-based pay expense and spent $175M repurchasing shares (repurchases can include shares withheld to cover employees' taxes). Repurchases were smaller than the stock pay, so they did little to offset new employee shares.Over three fiscal years Hims & Hers Health recorded $294M of stock-based pay expense and spent $175M repurchasing shares. Repurchases were smaller than the stock pay, so they did little to offset new employee shares.
Earnings slid into a loss. Loss per share this year after a profit last year.
Hims & Hers Health made a loss per share in its latest year after a profit the year before.
Much more borrowing than peers. Debt is 4.8× equity vs a peer median of 0.2×.Debt is 4.8× equity vs peers 0.2×.
Debt is 4.8× shareholders' equity, against a peer median of 0.2×, among the highest 10% of its peer group.Debt is 4.8× shareholders' equity, vs peers 0.2×, among the highest 10% of its peer group.
Investment surge. Capital spending 10% of revenue, up from 1.4% in 2022.
Hims & Hers Health is spending 10% of revenue on facilities and equipment, up from 1.4% in 2022. That weighs on free cash flow today; whether it pays off depends on the returns those investments earn.

StockQuotient Score

30/ 100

Oct 5 30 → Nov 4 30

Valuation

Is the price right?

8/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major changeValuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield
▼ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-2.4%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield-0.2%

Yahoo Finance fallback · SEC enterprise value unavailable (debt or EBITDA not reported in standard form) · trailing 12 monthsNegative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield1.0%

SEC filings · 12 months to Jun 2026 · operating cash flow − capital spendingReported value20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield5.4%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

82/100

Strong▼ 1 since Oct 27 close

3/3 inputs reported · High confidence

Since last quarter: ▲ Stronger

12-month revenue up 8.8%

Why it changed since the Oct 27, 2026 close: Score 83 → 82

Peer companies moved-1

Each step re-scores the company against its peers as they were on Oct 28, 2026; the parts add up to the change. Price effects on EBITDA yield are approximate.

Why

Stronger than most peers on:

▲ 3-yr revenue
▲ Revenue growth

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growthUnavailable

Earnings per share turned from a profit to a loss33% base weight · Z-score -1.99Sector median: 0.0976 · MAD: 0.2991

3-year revenue growth53.7%

SEC filings · 3 years to Jun 2026Reported value33% base weight · Z-score 5.69Sector median: 0.0584 · MAD: 0.0840

Revenue growth28.0%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 2.25Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

28/100

Weak

3/3 inputs reported · High confidence

Since last quarter: ▼ Weaker

Operating margin fell 4.7 points to -6.0%

Why

Weaker than most peers on:

▼ ROIC
▼ Operating margin
▼ ROA

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin-6.0%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -1.07Sector median: 0.0706 · MAD: 0.1217

Return on assets-3.9%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -1.04Sector median: 0.0166 · MAD: 0.0537

Return on invested capital-25.5%

Yahoo Finance fallback · SEC operating income or invested capital unavailable · trailing 12 monthsReported value33% base weight · Z-score -3.01Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin68.4%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-43.8%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Higher

Higher relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Weaker than most peers on:

▼ Beta
▼ Debt / equity
▼ Current ratio

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta2.43

Yahoo Finance · 5-year monthly beta vs the marketOutlier capped at sector 5th/95th percentile33% base weight · Z-score -4.28Sector median: 0.6250 · MAD: 0.3380

Current ratio0.93×

SEC filings · latest balance sheetReported value33% base weight · Z-score -1.19Sector median: 2.5860 · MAD: 1.3850

Debt / equity4.77×

Yahoo Finance fallback · no standard SEC debt tagOutlier capped at sector 5th/95th percentile33% base weight · Z-score -9.77Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Hims & Hers Health

Is Hims & Hers Health getting weaker?: Its latest SEC filing (Aug 10, 2026) got weaker in some ways: operating margin fell 4.7 points to -6.0%. Its overall score is unchanged at 30/100 since Oct 28, 2026.
How is Hims & Hers Health valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -2.4% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -2.4% vs peers 1.5% (weaker than 100% of peers).
Is Hims & Hers Health growing?: Yes, faster than most of its peers. Growth scores 82/100 against 1,393 healthcare peers. 3-year revenue growth 53.7% vs a peer median of 5.8% (stronger than 93% of peers).3-year revenue growth 53.7% vs peers 5.8% (stronger than 93% of peers).
How profitable is Hims & Hers Health?: Less profitable than most of its peers. Profitability scores 28/100 against 1,393 healthcare peers. Return on invested capital -25.5% vs a peer median of 4.7% (weaker than 81% of peers).Return on invested capital -25.5% vs peers 4.7% (weaker than 81% of peers).
How risky is Hims & Hers Health?: Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Beta 2.43 vs a peer median of 0.63 (weaker than 100% of peers).Beta 2.43 vs peers 0.63 (weaker than 100% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Aug 10, 2026 · compared with the quarter ended Mar 31, 2026

Got weaker

Operating margin fell 4.7 points to -6.0%

	Previous quarter	Latest quarter	Change
Revenue (12 months)	2.4B USD	2.6B USD	+8.8%
Net income (12 months)	−13.2M USD	−142.0M USD	+973.1%
Operating margin	-1.3%	-6.0%	−4.7 pts
Free cash flow (12 months)	60.4M USD	61.6M USD	+2.1%
Cash	222.3M USD	609.8M USD	+174.4%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Drug Manufacturers - Specialty & Generic · 27 companies

Valuations in Drug Manufacturers - Specialty & Generic are within their usual range since Jun 2020.

45% of months since Jun 2020 were valued lower than now.
24% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is +8% vs the whole market, against a usual +36%.

Jun 2020Shaded: most expensive fifth of its range2026

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Gross margin	75.2%	77.6%	82.0%	79.5%	73.8%	▼ 5.6 pts
Operating margin	-42.3%	-13.0%	-3.4%	4.2%	4.5%	▲ 0.3 pts
Net margin	-39.6%	-12.5%	-2.7%	8.5%	5.5%	▼ 3.1 pts
Return on assets (ROA)	-25.6%	-17.9%	-5.3%	17.8%	6.0%	▼ 12 pts
Return on equity (ROE)	-32.2%	-21.1%	-6.8%	26.4%	23.7%	▼ 2.7 pts
Free cash flow margin	-13.0%	-6.4%	5.4%	13.4%	2.4%	▼ 11 pts
Current ratio	3.41×	4.52×	3.00×	1.79×	1.90×	▲ 6.1%
Quick ratio	3.24×	4.07×	2.74×	1.50×	1.70×	▲ 14%
Interest coverage	—	—	—	—	—	—

HIMS price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Strength: growing faster than most peersgrowing faster than peers

Drawback: less profitable than most peersless profitable than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Drawback: higher risk than most peers: its share price swings more than most peers’ (beta 2.43 vs a peer median of 0.63), less short-term liquidity (current ratio 0.93 vs a peer median of 2.59) and more debt relative to equity (4.77× vs a peer median of 0.22×)higher risk: bigger price swings (beta 2.43 vs peers 0.63), less liquidity (current ratio 0.93 vs peers 2.59) and more debt vs equity (4.77× vs peers 0.22×)

Ranks #980 of 1,157 healthcare companies (bottom 16%)

See how it ranks against its peers

Worth knowing

Stock pay outran buybacks. Stock-based pay expense $294M vs $175M spent repurchasing shares over the 3 fiscal years to 2025.

Over three fiscal years Hims & Hers Health recorded $294M of stock-based pay expense and spent $175M repurchasing shares (repurchases can include shares withheld to cover employees' taxes). Repurchases were smaller than the stock pay, so they did little to offset new employee shares.Over three fiscal years Hims & Hers Health recorded $294M of stock-based pay expense and spent $175M repurchasing shares. Repurchases were smaller than the stock pay, so they did little to offset new employee shares.

Earnings slid into a loss. Loss per share this year after a profit last year.

Hims & Hers Health made a loss per share in its latest year after a profit the year before.

Much more borrowing than peers. Debt is 4.8× equity vs a peer median of 0.2×.Debt is 4.8× equity vs peers 0.2×.

Debt is 4.8× shareholders' equity, against a peer median of 0.2×, among the highest 10% of its peer group.Debt is 4.8× shareholders' equity, vs peers 0.2×, among the highest 10% of its peer group.

Investment surge. Capital spending 10% of revenue, up from 1.4% in 2022.

Hims & Hers Health is spending 10% of revenue on facilities and equipment, up from 1.4% in 2022. That weighs on free cash flow today; whether it pays off depends on the returns those investments earn.

Questions investors ask about Hims & Hers Health

Is Hims & Hers Health getting weaker?

Its latest SEC filing (Aug 10, 2026) got weaker in some ways: operating margin fell 4.7 points to -6.0%. Its overall score is unchanged at 30/100 since Oct 28, 2026.

How is Hims & Hers Health valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -2.4% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -2.4% vs peers 1.5% (weaker than 100% of peers).

Is Hims & Hers Health growing?

Yes, faster than most of its peers. Growth scores 82/100 against 1,393 healthcare peers. 3-year revenue growth 53.7% vs a peer median of 5.8% (stronger than 93% of peers).3-year revenue growth 53.7% vs peers 5.8% (stronger than 93% of peers).

How profitable is Hims & Hers Health?

Less profitable than most of its peers. Profitability scores 28/100 against 1,393 healthcare peers. Return on invested capital -25.5% vs a peer median of 4.7% (weaker than 81% of peers).Return on invested capital -25.5% vs peers 4.7% (weaker than 81% of peers).

How risky is Hims & Hers Health?

Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Beta 2.43 vs a peer median of 0.63 (weaker than 100% of peers).Beta 2.43 vs peers 0.63 (weaker than 100% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

2.4B USD

2.6B USD

+8.8%

Net income (12 months)

−13.2M USD

−142.0M USD

+973.1%

Operating margin

-1.3%

-6.0%

−4.7 pts

Free cash flow (12 months)

60.4M USD

61.6M USD

+2.1%

Cash

222.3M USD

609.8M USD

+174.4%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Gross margin

75.2%

77.6%

82.0%

79.5%

73.8%

▼ 5.6 pts

Operating margin

-42.3%

-13.0%

-3.4%

4.2%

4.5%

▲ 0.3 pts

Net margin

-39.6%

-12.5%

-2.7%

8.5%

5.5%

▼ 3.1 pts

Return on assets (ROA)

-25.6%

-17.9%

-5.3%

17.8%

6.0%

▼ 12 pts

Return on equity (ROE)

-32.2%

-21.1%

-6.8%

26.4%

23.7%

▼ 2.7 pts

Free cash flow margin

-13.0%

-6.4%

5.4%

13.4%

2.4%

▼ 11 pts

Current ratio

3.41×

4.52×

3.00×

1.79×

1.90×

▲ 6.1%

Quick ratio

3.24×

4.07×

2.74×

1.50×

1.70×

▲ 14%

Interest coverage

—